Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts

Goletz C, Lischke T, Harnack U, Schiele P, Danielczyk A, Rühmann J and Goletz S (2018) Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts. Front. Immunol. 9:1614. doi: 10.3389/fimmu.2018.01614

Read more
Phase I study of tomuzotuximab, a glycoemgineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas

Walter Fiedler, Sara Cresta, Henning Schulze-Bergkamen, Sara De Dosso, Jens Weidmann, Anna Tessari, Hans Baumeister, Antje Danielczyk, Bruno Dietrich, Steffen Goletz, Alfredo Zurlo, Marc Salzberg, Cristiana Sessa, Luca Gianni

Read more
A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials
2017 June; Human Reproduction, pp. 1–9, 2017.
doi:10.1093/humrep/dex220
Read more
Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy

Felix Hart, Antje Danielczyk and Steffen Goletz
Academic Editors: Stephan Hinderlich and Hans Henning von Horsten
2017 May; Bioengineering 2017, 4(2), 42; doi:10.3390/bioengineering4020042

Read more
A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas

Fiedler W, DeDosso S, Cresta S, Weidmann J, Tessari A, Salzberg M, Dietrich B, Baumeister H, Goletz S, Gianni L, Sessa C. Eur J Cancer. 2016 Aug;63:55-63. doi: 10.1016/j.ejca.2016.05.003.

Read more
Safety assessment of the commensal strain Bacteroides xylanisolvens DSM 23964.

Ulsemer P, Toutounian K, Schmidt J, Leuschner J, Karsten U, Goletz S. Regul Toxicol Pharmacol. 2012 Mar;62(2):336-46. doi: 10.1016/j.yrtph.2011.10.014.

Read more
Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab

Jeschke U, Wiest I, Schumacher AL, Kupka M, Rack B, Stahn R, Karsten U, Mayr D, Friese K, Dian D. Anticancer Res. 2012 May;32(5):2185-9.

Read more
Safety and tolerance of Bacteroides xylanisolvens DSM 23964 in healthy adults.

Ulsemer P, Toutounian K, Kressel G, Schmidt J, Karsten U, Hahn A, Goletz S. Benef Microbes. 2012 Jun 1;3(2):99-111. doi: 10.3920/BM2011.0051.

Read more
Preliminary safety evaluation of a new Bacteroides xylanisolvens isolate.

Ulsemer P, Toutounian K, Schmidt J, Karsten U, Goletz S. Appl Environ Microbiol. 2012 Jan;78(2):528-35. doi: 10.1128/AEM.06641-11.

Read more
Expression of CD175 (Tn), CD175s (sialosyl-Tn) and CD176 (Thomsen-Friedenreich antigen) on malignant human hematopoietic cells.

Cao Y, Merling A, Karsten U, Goletz S, Punzel M, Kraft R, Butschak G, Schwartz-Albiez R. Int J Cancer. 2008 Jul 1;123(1):89-99. doi: 10.1002/ijc.23493.

Read more